Contacter le RP

Pour utiliser cette fonctionnalité, vous devez bénéficier d'un compte Babbler.

arrow_back

Babbler permet aux journalistes et communicants de collaborer plus simplement.

En vous connectant, vous pourrez accéder gratuitement aux espaces presse des centaines d'entreprises de vos secteurs qui sont sur Babbler, entrer en contact direct avec leurs équipes RP mais aussi y partager vos prochains sujets !

Leurs espaces presse sont sur Babbler :

Vous êtes à 1 clic de l'inscription !

Précédent

Content de vous revoir !

Communiqué de presse

Glaucoma Therapeutics Market - Global Industry Insights, Opportunity Analysis, 2018-2026
timer minutes de lecture minute de lecture

Copier le lien
Glaucoma Therapeutics Market - Global Industry Insights, Opportunity Analysis, 2018-2026
<p>Glaucoma Therapeutics</p>

Cliquez sur l'image pour obtenir le format original

Glaucoma Therapeutics

Glaucoma refers to the group of conditions characterized by optic nerve damage, visual field loss, and secondary to retinal ganglion cell damage, which may lead to death. According to the International Agency for the Prevention of Blindness: 2017, glaucoma is second leading cause of blindness and leading cause of irreversible blindness worldwide. The most common types of glaucoma are Primary Open Angle Glaucoma (POAG) and Primary Angle Closure Glaucoma (PACG). Moreover, PACG is most common in South-East Asian population while POAG is most common in white Caucasians and individuals of African origin. PACG is associated with a high risk of blindness as compared to POAG.

Get Exclusive Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/1675

Increasing number of patients with glaucoma and increasing incidences of blindness are expected to be the major driving factor for growth of the global glaucoma therapeutics market. According to the International Agency for the Prevention of Blindness, 2010 data findings, it is estimated that by 2020, around 80 million people will suffer from glaucoma, with an increase of about 20 million form 2010. Furthermore, in 2010, over 8 million people were bilaterally blind due to glaucoma, which is expected to increase to over 11 million by 2020. The significant risk of developing glaucoma increases with geriatric population, increased intraocular pressure, positive family history for glaucoma, and ethnicity. According to the American Academy of Ophthalmology (AAO), 2016: the global prevalence of glaucoma is estimated to rise to 76 million in 2020 and 111.8 million in 2040.

Glaucoma may occur among the people with or without diabetes. Moreover, people with diabetic retinopathy have an increased risk of glaucoma. The condition is associated with abnormal blood vessel growth, which can result in retinopathy and leads to blockage of natural drainage of the eye. Rapidly increasing geriatric population is one of the important factors for increasing prevalence of glaucoma, which in turn is projected to drive growth of the glaucoma therapeutics market in near future. For instance, according to the International Diabetes Foundation (IDF) 2017 statistics, the number of people with diabetes aged between 20 to 79 years are increasing worldwide. Among which, Africa (156%) is accounted to register the highest diabetic population, followed by Middle East (110%), South East Asia (84%), Latin and Central America(62%), North America (35%), Europe (16%), and Western Pacific (15%).

Some of the key players operating in the glaucoma therapeutics market include Valeant Pharmaceuticals International, Inc., Allergan Inc., Merck KGaA, Fera Pharmaceuticals, LLC, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Aristo Pharmaceuticals Pvt. Ltd., Santen Pharmaceutical Co., Ltd., Aerie Pharmaceuticals, and Novartis AG. Key players in the market are focusing on organic growth strategies in order to gain maximum market share and retain leading position in the market.

Read Full Report with TOC @ https://www.coherentmarketinsights.com/ongoing-insight/toc/1675

For instance, in December 2017, Aerie Pharmaceuticals, Inc. received the U.S. Food and Drug Administration (FDA) approval for Rhopressa (netarsudil ophthalmic solution) 0.02%, indicated for lowering of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave, 

#3200 

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

  • Business
  • Business Consulting Services
  • Health & Medicine
  • Medicine

Autres actualités de la marque

inscrit avec succès

Félicitations, vous êtes inscrit sur BABBLER !

Pour découvrir dès maintenant toutes les actualités qui vous attendent sur Babbler, consultez votre newsfeed !

Vos domaines ont été préselectionnés. Vous pouvez les compléter en cliquant ici

  • Business
  • Business Consulting Services
  • Health & Medicine